English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 11 February 2021, 11:00 HKT/SGT
Share:
        

Source: Apollomics, Inc. / Iterion Therapeutics
Apollomics, Inc. and Iterion Therapeutics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Tegavivint in Greater China
Agreement will expand clinical development for a potent and selective small molecule targeting TBL1, a downstream target in the Wnt/Beta-catenin signaling pathway

Foster City, CA, Hangzhou, CH and Houston, TX, Feb 11, 2021 - (ACN Newswire) - Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, and Iterion Therapeutics, Inc., a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, today announced an exclusive collaboration and license agreement for the development and commercialization of tegavivint in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China.

Tegavivint is a potent and selective inhibitor of nuclear Beta-catenin that works through binding to TBL1 (Transducin Beta-like Protein One), a downstream target in the Wnt-signaling pathway. Iterion is pursuing the development of Tegavivint for the treatment of cancers where nuclear Beta-catenin signaling is known to play a role. Tegavivint is currently the subject of a Phase 1/2a clinical trial in patients with progressive desmoid tumors.

"As a potent and selective small molecule targeting the Wnt-signaling pathway, Tegavivint is an ideal addition to our clinical development pipeline," said Guo-Liang Yu, Ph.D., Chief Executive Officer of Apollomics. "The preclinical work has demonstrated that the differentiated mechanism of action may be applicable in several indications as both a monotherapy and a combination treatment. We look forward to working with the Iterion team to expand development in Greater China."

Under the terms of the agreement, Apollomics will be responsible for clinical development and commercialization in Greater China. Apollomics and Iterion will form a joint development committee to ensure ongoing collaboration of Tegavivint across indications and geographies. Iterion has received an initial cash payment for ongoing research and development costs in connection with the company's global development of Tegavivint. Iterion is also eligible to receive potential development and sales milestone payments, as well as tiered royalties on net sales. Apollomics will be responsible for all costs related to development and commercialization activities for Tegavivint in Greater China.

Rahul Aras, Ph.D., President and Chief Executive Officer, Iterion Therapeutics, added, "As we explore multiple indications for Tegavivint in the U.S., including desmoid tumors, acute myeloid leukemia, non-small cell lung cancer, and pediatric cancers, we are excited to partner with Apollomics to expand its development and potential commercialization in Greater China. With Apollomics' oncology focus and growing footprint in China, they are the partner of choice to successfully advance Tegavivint for cancer patients in this region."

About Tegavivint

Tegavivint is a potent and selective inhibitor of nuclear Beta-catenin that binds to TBL1 (Transducin Beta-like Protein One), a downstream target in the Wnt-signaling pathway. Targeting TBL1 may enable specific silencing of Wnt-pathway oncogenic gene expression without affecting other necessary cellular functions that are disrupted when targeting higher up the Wnt-pathway. This avoids toxicity issues common to other drugs in this pathway.

Tegavivint has the potential for clinical utility in multiple cancer types. Tegavivint is currently the subject of a Phase 1/2a clinical trial in progressive desmoid tumors. Desmoid tumors, a rare type of sarcoma for which there is no currently approved therapy, are driven primarily by nuclear Beta-catenin signaling and, thus, present an optimal indication for demonstrating the drug's mechanism of action as the company pursues additional clinical programs. Tegavivint has also demonstrated anti-tumor activity in multiple pre-clinical models, including acute myeloid leukemia (AML) and non-small cell lung cancer (NSCLC).

About Iterion Therapeutics

Iterion Therapeutics is a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics. The company's lead product, Tegavivint, is a potent and selective inhibitor of nuclear Beta-catenin, an oncology target implicated in cell proliferation, differentiation, immune evasion and stem cell renewal. Research demonstrating anti-tumor activity in multiple pre-clinical models indicate that Tegavivint has the potential for clinical utility in multiple cancer types. Tegavivint is currently the subject of a Phase 1/2a clinical trial in patients with progressive desmoid tumors. Iterion is also pursuing development in additional cancers where nuclear Beta-catenin signaling has been shown to play a role, including acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC), and pediatric cancers, including sarcomas, lymphoma and other solid tumors. This research/clinical trial was supported with a $15.9 million grant from the Cancer Prevention & Research Institute of Texas. For more information on Iterion, please visit https://iteriontherapeutics.com.

About Apollomics, Inc.

Apollomics, Inc. is an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's existing pipeline consists of several development-stage assets, including novel, humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. For more information, please visit www.apollomicsinc.com.

Iterion Therapeutics Contact:

Tiberend Strategic Advisors, Inc.
Ingrid Mezo (Media)
646-604-5150
imezo@tiberend.com

Apollomics Contacts:

Investor Contact:
Wilson W. Cheung
Chief Financial Officer
(650) 209-4436
wcheung@apollomicsinc.com

U.S. Media Contact:
Remy Bernarda
Corporate Communications
(415) 203-6386
remy.bernarda@apollomicsinc.com

China Media Contact:
Porda Havas International
Kelly Fung
General Manager
(852) 3150 6763
kelly.fung@pordahavas.com

Phoenix Fung
Assistant Vice President
(852) 3150 6773
phoenix.fung@pordahavas.com

Topic: Press release summary
Source: Apollomics, Inc. / Iterion Therapeutics

Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Apollomics, Inc. Releated News
Aug 10, 2021 11:55 HKT/SGT
冠科美博(APOLLOMICS)APL-102 中国I期临床研究完成首例患者给药
Aug 10, 2021 11:54 HKT/SGT
冠科美博(APOLLOMICS)APL-102 中國I期臨床研究完成首例患者給藥
Aug 10, 2021 11:53 HKT/SGT
Apollomics, Inc. Doses First Patient in a Phase I Clinical Trial of APL-102
May 20, 2021 13:38 HKT/SGT
冠科美博上海分公司正式开业
May 20, 2021 13:37 HKT/SGT
冠科美博上海分公司正式開業
More news >>
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575